• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Ultragenyx to Participate in Investor Conferences in December

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635

    GLOBENEWSWIRE

    Ultragenyx Updates on GTX-102 in Angelman Syndrome at FAST Summit

    GLOBENEWSWIRE

    Ultragenyx Reports Q3 2024 Financial Results & Corporate Update

    GLOBENEWSWIRE

    Ultragenyx to Host Call for Q3 2024 Results and Update

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4).

    GLOBENEWSWIRE

    Ultragenyx Receives Breakthrough Designation For Setrusumab

    GLOBENEWSWIRE

    Ultragenyx tweaks gene therapy dosing to dial up efficacy

    FIERCE BIOTECH

    Ultragenyx Updates On Cyprus2+ Study Of UX701 For Wilson Disease

    GLOBENEWSWIRE

    INKmune Demonstrates Safety And NK-Cell Activity In First Cohort

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Rule

    GLOBENEWSWIRE

    Ultragenyx to Participate in Investor Conferences in September

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Amlogenyx Closes Seed Funding Led By GordonMD® Global

    BUSINESSWIRE

    Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

    GLOBENEWSWIRE

    Ultragenyx To Host Q2 2024 Results And Update Call

    GLOBENEWSWIRE

    Ultragenyx To Update On GTX-102 For Angelman Syndrome At ASF Event

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx Completes FDA End-Of-Phase 2 Meeting For GTX-102

    GLOBENEWSWIRE

    Ultragenyx eyes accelerated US filing for Sanfilippo gene therapy

    FIERCE BIOTECH

    Ultragenyx Prices Public Offering Of Common Stock, Pre-Funded Warrants

    GLOBENEWSWIRE

    Ultragenyx, Mereo`s brittle bone drug sustains fracture rate cut

    FIERCE BIOTECH

    Ultragenyx & Mereo BioPharma Announce New Pha2 Data from Phase 2/3 Orbit Study

    GLOBENEWSWIRE

    Ultragenyx: Participating At Goldman Sachs Healthcare Conference

    GLOBENEWSWIRE

    Ultragenyx Positive Phase 3 Results For DTX401 In Glycogen Storage Disease

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx to Participate at Bank of America`s 2024 Healthcare Conference

    GLOBENEWSWIRE

    Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

    GLOBENEWSWIRE

    Ultragenyx Completes Enrollment in Ph3 Setrusumab OI Studies ORBIT, COSMIC

    GLOBENEWSWIRE

    Ultragenyx Issues 2023 Corporate Responsibility Report

    GLOBENEWSWIRE

    Ultragenyx Hosts Q1 2024 Call and Corporate Update

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx says Angelman therapy is working, but safety questions remain

    BIOPHARMADIVE

    Ultragenyx AAN 2024 Data Presentations

    GLOBENEWSWIRE

    Ultragenyx Updates GTX-102 Angelman Data Timing

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx to Participate at Investor Conferences in March

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Results

    GLOBENEWSWIRE

    Ultragenyx Announces Data Demonstrating Treatment with UX111 Results

    GLOBENEWSWIRE

    Ultragenyx boosts case for new surrogate biomarker

    ENDPTS

    Ultragenyx Receives PRIME Designation from EMA for GTX-102

    GLOBENEWSWIRE

    Ultragenyx Announces Completion of Dosing in Phase 1/2/3 Study Evaluating UX701

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx nears $50M Series A for its Alzheimer`s gene therapy spinout: #JPM24

    ENDPTS

    Ultragenyx Reports Preliminary 2023 Revenue

    GLOBENEWSWIRE

    Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza

    GLOBENEWSWIRE

    Ultragenyx Announces Completion of Enrollment in Phase 1/2 Trial of GTX-102

    GLOBENEWSWIRE

    Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Andelyn Selected by Ultragenyx for PPQ Manufacturing for Sanfilippo Syndrome

    PR NEWSWIRE

    Ultragenyx Receives EC Decision for Evkeeza® (evinacumab) Expanded Indication

    GLOBENEWSWIRE

    Ultragenyx to Participate at Investor Conferences in November

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Ultragenyx to Participate in the Jefferies London Healthcare Conference

    GLOBENEWSWIRE

    Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

    GLOBENEWSWIRE

    Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Ultragenyx Announces Closing of Public Offering of Common Stock

    GLOBENEWSWIRE

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.